Dr. AloĂŻse Mabondzo | drug design | Best Researcher Award

Dr. AloĂŻse Mabondzo | drug design | Best Researcher Award

Doctorate at CEA, France

Professional Profiles

Google Scholar

Scopus

Orcid

🎓 Educational Background

Dr. Aloïse Mabondzo, has a distinguished academic foundation. He earned his Master’s degree in Molecular and Cellular Biology from the University of Strasbourg, France (1986-1989). Driven by a passion for cutting-edge research, he pursued a PhD in Virology and Immunology at the prestigious Pierre and Marie Curie University, France (1989-1993). His doctoral work focused on Active Immunotherapy using bispecific antibodies against HIV, a testament to his early commitment to tackling global health challenges.

đź§Ş Professional Positions

Dr. Mabondzo’s illustrious career began with a Post-doctoral Research Fellowship (1993-1997) at the CEA Neurovirology Department, where he made significant contributions to the field of neurovirology. In 1998, he joined the CEA Medicine and Healthcare Technologies Department, where he has served as Research Director and Head of the Neurovascular Unit Research and Therapeutic Innovation Laboratory. His leadership in these roles has driven breakthroughs in neurovascular research. Since 2019, Dr. Mabondzo has also been the Co-founder and Research Director of Ceres Brain Therapeutics, a startup dedicated to pioneering therapeutic innovations.

👩‍🏫 Mentoring and Supervision

Dr. Mabondzo has a proven track record as a mentor and supervisor. Over his career, he has supervised 16 PhD candidates (10 past, 6 current), 7 Postdoctoral Fellows (4 past, 3 current), and several other researchers, including 2 Research Assistants, 2 Engineers, and 2 Technicians. His mentorship has nurtured the next generation of scientists, fostering innovation and collaboration.

Publications Top Noted📄 

Dodecyl creatine ester therapy: from promise to reality

Authors: Mabondzo, A.; van de Kamp, J.; Mercimek-Andrews, S.

Journal: Cellular and Molecular Life Sciences

Year: 2024

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases

Authors: Angeli, E.; Paris, J.; Le Tilly, O.; Paintaud, G.; Bousquet, G.

Journal: Experimental Hematology and Oncology

Year: 2024

Impaired brain glucose metabolism as a biomarker for evaluation of dodecyl creatine ester in creatine transporter deficiency: Insights from patient brain-derived organoids and in vivo [18F]FDG PET imaging in a mouse model

Authors: Disdier, C.; Soyer, A.; Broca-Brisson, L.; Tournier, N.; Mabondzo, A.

Journal: Neurobiology of Disease

Year: 2024

Targeting the Multiple Complex Processes of Hypoxia-Ischemia to Achieve Neuroprotection

Authors: MaĂŻza, A.; Hamoudi, R.; Mabondzo, A.

Journal: International Journal of Molecular Sciences

Year: 2024

Epigenetic alterations in creatine transporter deficiency: a new marker for dodecyl creatine ester therapeutic efficacy monitoring

Authors: Broca-Brisson, L.; Disdier, C.; Harati, R.; Hamoudi, R.; Mabondzo, A.

Journal: Frontiers in Neuroscience

Year: 2024

Dr. sherif Hosny, Medicinal Chemistry, Best Researcher Award

Dr. sherif Hosny, Medicinal Chemistry, Best Researcher Award

Doctorate at EHA, Egypt

Professional Profiles

Google Scholar 

Scopus

🎓 Educational Background

He attended German School Dokki, Cairo from 1984 to 1994, achieving his Abitur with a grade of 1.9. From 1994 to 1998, he studied at the Faculty of Pharmacy, Cairo University, where he earned a Bachelor’s Degree in Pharmaceutical Science, graduating with Excellent with honors.In March 2000, he began his postgraduate studies at the Faculty of Pharmacy, Cairo University, registering for a Master’s degree in pharmaceutical science, specializing in the pharmacognosy department. His research focused on the topic: “A Contribution to the Study of Certain Hepatoprotective Plants Belonging to Family Apiaceae and Asteraceae.” Between 2005 and 2007, he completed a Diploma in Health Care Administration at the American University in Cairo.

In April 2008, he participated in a Fellowship at St. Jude Children’s Hospital. In September 2010, he registered for an MSc in Clinical Pharmacy at the Faculty of Pharmacy, Cairo University. He furthered his education by attending the Basis and Intermediate Master Class in Oncology Pharmacy in Vienna, Austria in October 2012, followed by the Advanced Master Class in Oncology Pharmacy in Dresden, Germany in October 2013.He obtained a Master’s Degree in Pharmaceutical Science, specializing in Clinical Pharmacy from the Faculty of Pharmacy, Cairo University in September 2015. His thesis was titled: “The Use of Valproic Acid in Pediatric Oncology Setting.” In 2016, he became a Certified Professional Trainer through the American University in Cairo. Finally, in September 2018, he became a PhD Candidate in Pharmaceutical Science, specializing in Clinical Pharmacy. His research topic is: “Evaluation of Antimicrobial Stewardship Program in Pediatric Oncology.”

🏆 Awards

He has received several prestigious awards, including the German President Award for Students, an Award from the Egyptian Hospital Pharmacist Association, and the First Lady Award for Excellence in 2010. He was recognized at the 1st Student Development Conference at Sinai University in 2010 and received the Egyptian Pharmacy Syndicate Award in the same year. Most recently, he earned the Best Pharmacist Award in 2018 from the Egyptian Pharmacy Syndicate CME Committee.

đź’Ľ Work Experience

From May 1998 to September 2002, he worked as a Clinical Pharmacist at the National Cancer Institute, Cairo University. His key responsibilities included the I.V. admixture of antibiotics and cytotoxic agents, leading the Clinical Pharmacy Development Program, and serving as the Senior Clinical Pharmacist and Night Shift Manager. His achievements include establishing Policies, Procedures, and Guidelines for the Oncology Clinical Pharmacy and overseeing operations as Senior Pharmacist.From 1999 to 2006, he served as a Senior Clinical Pharmacy Consultant at the Domiatta Cancer Institute, Egyptian Ministry of Health, where he managed the Clinical Pharmacy Development Program and established a protocol book for oncology clinical practices. He directed Annual Strategic Planning for clinical pharmacy services.

He also worked at the Tanta Cancer Institute and Menia Cancer Institute as a Senior Clinical Pharmacy Consultant from 1999 to 2000, leading the Clinical Pharmacy Development Program and training nursing staff in oncology pharmacy practices. His achievements included developing Oncology Clinical Pharmacy Guidelines and designing an Oncology Nurse Training Program.From 2001 to 2007, he continued as a Senior Clinical Pharmacy Consultant at the Sohag Cancer Institute, where he led the Clinical Pharmacy Development Program and developed a protocol book, directing Annual Strategic Planning and establishing policies for oncology pharmacy.

From 2008 to 2009, he worked at Frensh Qasr El Eini, Cairo University, where he managed the Clinical Pharmacy Development Program and created a protocol book, implementing clinical pharmacy policies and planning procedures.Finally, from April 1999 to 2006, he was a Teaching Assistant in the Pharmacognosy Department at the Faculty of Pharmacy, Cairo University (Beni Suef). His responsibilities included preparing lab equipment, delivering lectures, and supervising students. His achievements enhanced Pharmacognosy teaching methods and improved student engagement.

publications Top Notedđź“„

SIOPE and ESOP recommendations for extemporaneous compounding of oral liquid medicine formulations in pediatric oncology

Authors: Otsokolhich, M., Annereau, M., Bauters, T., Vassal, G., Buraja, S.

Journal: EJC Paediatric Oncology

Year: 2024

Correlation of Genetic Polymorphism of CYP3A5 to Cyclophosphamide Efficacy and Toxicity in Rhabdomyosarcoma Pediatric Egyptian Cancer Patients

Authors: ElShereef, C.E., Zaki, H.F., Badary, O.A., El Naga, S.A., Saber, M.M.

Journal: Asian Pacific Journal of Cancer Prevention

Year: 2024

Optimizing vancomycin therapeutic drug monitoring compliance in pediatric oncology: towards personalized medication management

Authors: Mohamed, R.G., Saber, R., Hussein, M.A., Shalaby, L., Nagy, M.

Journal: Personalized Medicine

Year: 2024

Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients

Authors: Shalaby, N., Zaki, H.F., Badary, O.A., Abouelnaga, S., Saber, M.M.

Journal: Asian Pacific Journal of Cancer Prevention

Year: 2024

Current status of African pediatric oncology education efforts aligned with the Global Initiative for Childhood Cancer

Authors: van Heerden, J., Lisa Christine, I., Downing, J., Balagadde-Kambugu, J., Geel, J.

Journal: Pediatric Hematology and Oncology

Year: 2023

 

Prof Dr. Rasim Mogulkoc | Medicinal Chemistry | Best Researcher Award |1056

Prof Dr. Rasim Mogulkoc | Medicinal Chemistry | Best Researcher Award

Doctorate at Selçuk University, Turkey

Professional Profile:

Google Scholar

Scopus

Orcid

Early Life and Education 🏫:

Prof. Dr. Rasim Mogulkoc was born on March 20, 1967, in Gürün (Sivas), Turkey. He completed his primary, secondary, and high school education in his hometown. In 1991, he graduated from Fırat University, marking the beginning of his journey in the medical and physiological sciences. Following his graduation, he completed his mandatory military service in 1992.

Academic Pursuits and Professional Journey 📚:

Prof. Mogulkoc embarked on his doctoral studies in 1993 and earned his Ph.D. in 1997. He began his academic career at Fırat University, serving as an assistant professor from 1997 to 2000. In November 2000, he joined Selcuk University Meram Faculty of Medicine as an assistant professor. His dedication to cardiovascular physiology led him to the University of Melbourne's Howard Florey Institute of Experimental Physiology and Medicine, where he conducted significant research from November 2000 to September 2001.

Rising Through the Ranks 🏅:

Prof. Mogulkoc's expertise and contributions to the field were recognized when he became an associate professor in November 2003. His continued excellence in research and teaching culminated in his promotion to professor at Selçuk University Faculty of Medicine in August 2010, a position he holds to this day.

Research Contributions and Innovations đź§ :

Prof. Mogulkoc has an impressive portfolio of research and innovations. He has completed or is currently working on 15 research projects. His work is widely cited, with a citation index of 27 on the Web of Science. He has published 160 journal articles in prestigious indexed journals and holds three editorial appointments. His primary areas of research include brain ischemia-reperfusion and the effects of flavonoids.

Collaborations and Memberships 🤝:

Prof. Mogulkoc has been part of significant research collaborations and holds memberships in two professional organizations. His contributions to the field have established him as a key figure in physiological research, particularly in his specialized areas.

Notable Publications:

Paper Title: Effect of 2-Week Naringin Supplementation on Neurogenesis and BDNF Levels in Ischemia–Reperfusion Model of Rats

    • Authors: Gungor Satilmis, Muammer Erbayraktar, Hakan Erbayraktar
    • Journal: Neurochemical Research
    • Volume: 42
    • Issue: 10
    • Pages: 2786-2797
    • Year: 2017

Paper Title: Marginal Maternal Zinc Deficiency Produces Liver Damage and Altered Zinc Transporter Expression in Offspring Male Rats

    • Authors: Renata Franciscato Cozzolino, Tania Bracht, Monica Soares Saldiva, Maria Regina Barbosa de Lima Couto, Ana Maria Sales Nogueira da Costa
    • Journal: Nutrients
    • Volume: 9
    • Issue: 6
    • Pages: 675
    • Year: 2017

Paper Title: The relationship between beta cell activation and SLC30A8/ZnT8 levels of the endocrine pancreas and maternal zinc deficiency in rats

    • Authors: Magali Waiz, Mouloud Zemour, Monique Toury, Joel Chappuis, Valerie Fages, Karim Bennani-Baiti
    • Journal: The Journal of Endocrinology
    • Volume: 232
    • Issue: 2
    • Pages: 229-240
    • Year: 2017

Paper Title: Melatonin protects retinal tissue damage in streptozotocin-induced aged rats

    • Authors: Canan TĂĽrkmen, Nesrin Kalender, Aysel Akay
    • Journal: Experimental Eye Research
    • Volume: 160
    • Issue: -
    • Pages: 127-137
    • Year: 2017

Paper Title: Zinc Ameliorates Nogo-A Receptor and Osteocalcin Gene Expression in Memory-Sensitive Rat Hippocampus Impaired by Intracerebroventricular Injection of Streptozotocin

    • Authors: Liao Jiang, Zhigang Yu, Li Xu, Fengjiao Zhang, Yonghua Chen
    • Journal: Biological Trace Element Research
    • Volume: 176
    • Issue: 1
    • Pages: 196-205
    • Year: 2017